Lee J, Mumaw D, Liu P, Loving B, Sebastian E, Cong X
Adv Radiat Oncol. 2024; 9(11):101632.
PMID: 39610800
PMC: 11603120.
DOI: 10.1016/j.adro.2024.101632.
Koontz B, Koritzinsky M, Zoberi J, Brown S, Ding X, Wong J
J Appl Clin Med Phys. 2024; 25(11):e14533.
PMID: 39447139
PMC: 11539965.
DOI: 10.1002/acm2.14533.
Rykkelid A, Sinha P, Folefac C, Horsman M, Sorensen B, Soland T
Sci Rep. 2024; 14(1):11569.
PMID: 38773258
PMC: 11109162.
DOI: 10.1038/s41598-024-62272-z.
Skalina K, Malachowska B, Sindhu K, Thompson M, Nehlsen A, Salgado L
BJUI Compass. 2024; 5(3):334-344.
PMID: 38481668
PMC: 10927934.
DOI: 10.1002/bco2.316.
Chimote A, Lehn M, Bhati J, Mascia A, Sertorio M, Lamba M
Cancers (Basel). 2024; 16(5).
PMID: 38473367
PMC: 10931005.
DOI: 10.3390/cancers16051008.
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
Corrigan K, Xu T, Sasaki Y, Lin R, Chen A, Welsh J
Radiother Oncol. 2024; 193:110121.
PMID: 38311031
PMC: 10947851.
DOI: 10.1016/j.radonc.2024.110121.
Modulation of CD8 T Cell Responses by Radiotherapy-Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors.
Jeon S, Song C, Eom K, Kim I, Kim J
Int J Mol Sci. 2023; 24(23).
PMID: 38069014
PMC: 10706388.
DOI: 10.3390/ijms242316691.
Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers.
Cheng S, Li B, Yu J, Wang L
Chin J Cancer Res. 2023; 35(5):483-500.
PMID: 37969961
PMC: 10643341.
DOI: 10.21147/j.issn.1000-9604.2023.05.06.
Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy.
Su C, Himes J, Kirsch D
Int Rev Cell Mol Biol. 2023; 378:201-232.
PMID: 37438018
PMC: 10710768.
DOI: 10.1016/bs.ircmb.2023.03.006.
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations.
Karapetyan L, Iheagwara U, Olson A, Chmura S, Skinner H, Luke J
J Natl Cancer Inst. 2023; 115(11):1278-1293.
PMID: 37348864
PMC: 10637035.
DOI: 10.1093/jnci/djad118.
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q
JCI Insight. 2023; 8(12).
PMID: 37345658
PMC: 10371249.
DOI: 10.1172/jci.insight.167749.
Ultra-high dose-rate proton FLASH improves tumor control.
Shukla S, Saha T, Rama N, Acharya A, Le T, Bian F
Radiother Oncol. 2023; 186:109741.
PMID: 37315577
PMC: 10527231.
DOI: 10.1016/j.radonc.2023.109741.
Clinical Impact of Proton Beam Therapy for Postoperative Lymph Node Oligorecurrence of Esophageal Cancer.
Hiroshima Y, Ishikawa H, Sumiya T, Murakami M, Nakamura M, Ishida T
In Vivo. 2023; 37(3):1253-1259.
PMID: 37103111
PMC: 10188010.
DOI: 10.21873/invivo.13202.
Photon- and Proton-Mediated Biological Effects: What Has Been Learned?.
Jumaniyazova E, Smyk D, Vishnyakova P, Fatkhudinov T, Gordon K
Life (Basel). 2023; 13(1).
PMID: 36675979
PMC: 9866122.
DOI: 10.3390/life13010030.
Particle Therapy: Clinical Applications and Biological Effects.
Kiseleva V, Gordon K, Vishnyakova P, Gantsova E, Elchaninov A, Fatkhudinov T
Life (Basel). 2022; 12(12).
PMID: 36556436
PMC: 9785772.
DOI: 10.3390/life12122071.
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.
Cesaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P
Cancers (Basel). 2022; 14(12).
PMID: 35740495
PMC: 9221493.
DOI: 10.3390/cancers14122829.
Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.
Gupta K, Jones J, de Araujo Farias V, Mackeyev Y, Singh P, Quinones-Hinojosa A
Front Oncol. 2022; 12:840241.
PMID: 35664781
PMC: 9158132.
DOI: 10.3389/fonc.2022.840241.
Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su C, Hou M, Huang P, Chou Y, Huang B, Tseng J
Am J Cancer Res. 2022; 12(4):1606-1620.
PMID: 35530291
PMC: 9077059.
Radiation-Induced Fibrotic Tumor Microenvironment Regulates Anti-Tumor Immune Response.
Nam J, Kim J, Park M, Kim E, Kim J, Lee Y
Cancers (Basel). 2021; 13(20).
PMID: 34680381
PMC: 8533839.
DOI: 10.3390/cancers13205232.
Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies.
Boustani J, Lecoester B, Baude J, Latour C, Adotevi O, Mirjolet C
Cancers (Basel). 2021; 13(19).
PMID: 34638376
PMC: 8508444.
DOI: 10.3390/cancers13194893.